Europe Medical Marijuana Market Forecast to 2028 – Regional Analysis – by Product Type (Dried Form and Extract Form), Application (Pain Management, Tourette’s, Alzheimer’s Disease, Migraines, Depression and Anxiety, Multiple Sclerosis, Cancer, and Others)

Europe Medical Marijuana Market Forecast to 2028 – Regional Analysis – by Product Type (Dried Form and Extract Form), Application (Pain Management, Tourette’s, Alzheimer’s Disease, Migraines, Depression and Anxiety, Multiple Sclerosis, Cancer, and Others), and Distribution Channel (Retail Pharmacy, E-Commerce, and Others)

The Europe medical marijuana market is expected to grow from US$ 3,414.26 million in 2022 to US$ 9,703.38 million by 2028. It is estimated to register a CAGR of 19.0% from 2022 to 2028.

Increasing Approvals of Medical Marijuana Fuels Europe Medical Marijuana Market Growth

Recent initiatives related to the legality of medical marijuana in Europe have been indicative of a broader trend toward acceptance and acknowledgment of the therapeutic potential of cannabis. Germany, for instance, stands as one of the leaders in its robust medical marijuana market, having legalized it in 2017. The country has expanded the list of eligible medical conditions for cannabis treatment, witnessing a surge in patient registrations and imports of medical marijuana. France embarked on a two-year pilot program in 2021 to assess the feasibility and efficacy of medical cannabis for specific ailments, marking a notable step forward. The UK legalized medical marijuana in 2018, permitting a specialist doctor to prescribe cannabis-based products for specific medical conditions. However, access issues have prompted a government review to improve patient accessibility.

Moreover, Italy boasts an established medical cannabis program that caters to patients with various conditions, with ongoing efforts to streamline regulations and broaden access. The Netherlands, renowned for its progressive drug policies, provides access to medical marijuana through pharmacies. Also, Luxembourg announced plans to become the first European nation to fully legalize recreational cannabis use, signaling evolving attitudes toward cannabis. Greece, on the other hand, legalized medical cannabis in 2017, encouraging investments in cultivation, processing, and distribution. These developments collectively reflect the shifting landscape of medical marijuana in Europe, with an increasing number of countries recognizing its therapeutic value for patients with specific medical needs.

Europe Medical Marijuana Market Overview

The Europe medical marijuana market is divided into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The Europe region holds a significant market share in the medical marijuana market. Europe occupies a significant position in the Europe medical marijuana market and is estimated to register a robust growth rate over the forecast period. The market growth in the region is attributed to the growing life science research and increasing investment in research and development.

Europe Medical Marijuana Market Revenue and Forecast to 2028 (US$ Million)

Europe Medical Marijuana Market Segmentation

The Europe medical marijuana market is segmented into product type, application, distribution channel, and country.

Based on product type, the Europe medical marijuana market is segmented into dried form and extract form. The extract form segment held a larger share of the Europe medical marijuana market in 2022.

Based on application, the Europe medical marijuana market is segmented into pain management, Tourette’s, Alzheimer’s disease, migraines, depression and anxiety, multiple sclerosis, cancer, and others. The pain management segment held the largest share of the Europe medical marijuana market in 2022.

Based on distribution channel, the Europe medical marijuana market is segmented into retail pharmacy, e-commerce, and others. The retail pharmacy segment held the largest share of the Europe medical marijuana market in 2022.

Based on country, the Europe medical marijuana market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe medical marijuana market in 2022.

Aphria, Inc.; Canopy Growth Corporation; GW Pharmaceuticals; Panaxia Pharmaceutical Industries Ltd.; and VIVO Cannabis Inc are some of the leading companies operating in the Europe medical marijuana market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe medical marijuana market .
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Europe medical marijuana market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.